Updated clinical practice guidelines provide evidence-based recommendations for systemic therapy in hepatocellular carcinoma management. Researchers highlight the introduction of new targeted therapies and immune-checkpoint inhibitors to address critical issues, including recurrence after curative treatment and disease progression among patients ineligible for other therapies. Enhanced understanding of immune-related adverse events contributes to improved patient management. This guideline emphasizes targeted approaches, ensuring optimal treatment pathways for patients suffering from this high-mortality cancer.
Editorial by Lau G, Obi S (…) Omata M et 55 al. in Hepatol Int
© 2024. Asian Pacific Association for the Study of the Liver.